tirzepatide for cardiovascular disease outcomes trial results august 2025 compared with semaglutide and 10-year risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 Tirzepatide and the 10‐year predicted – Tirzepatide and Cardiovascular Health: Protect

Instead, we offer Lipofirm, a safe and approved alternative for fat reduction and body contouring

Different patient populations, different enrollment criteria, different sites, and different measurement protocols all introduce variability that makes direct numerical comparison imprecise

GLP-1 Success Starts with Dietitian Leadership It should come as no surprise that a large part of the success with incretin-based therapies like Ozempic, Wegovy, Mounjaro, and Zepboundstems from the effective integration of lifestyle modifications, particularly nutrition

How GLP1 medications suppress appetite Understanding the appetite mechanism helps explain why responses vary

Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke